<?xml version="1.0" encoding="UTF-8"?>
<ref id="B12">
 <label>12</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>D’Adamo</surname>
    <given-names>DR</given-names>
   </name>
   <name>
    <surname>Dickson</surname>
    <given-names>MA</given-names>
   </name>
   <name>
    <surname>Keohan</surname>
    <given-names>ML</given-names>
   </name>
   <name>
    <surname>Carvajal</surname>
    <given-names>RD</given-names>
   </name>
   <name>
    <surname>Hensley</surname>
    <given-names>ML</given-names>
   </name>
   <name>
    <surname>Hirst</surname>
    <given-names>CM</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors</article-title>. 
  <source>Oncologist</source> (
  <year>2019</year>) 
  <volume>24</volume>(
  <issue>6</issue>):
  <page-range>857–63</page-range>. 
  <pub-id pub-id-type="doi">10.1634/theoncologist.2018-0160</pub-id>
 </mixed-citation>
</ref>
